Podcast
 |
| Jerry Flanagan, healthcare policy director for ConsumerWatchdog, discusses his group’s lawsuit against Anthem Blue Cross of California over its rate hikes, what they mean for healthcare reform, and why the proposed healthcare legislation wouldn’t have prevented Anthem from instituting the rate increases in the first place. |
G. Steven Burrill
Welcome from the CEO
Flash required to view this video. Download the latest version here
G. Steven BurrillNews
Biotech posts gain in February as broader markets strengthen March 03, 2010 | Press Release
Biotech holds steady in January as broader markets head south February 01, 2010 | Press Release
Biotech Closes the Year on an Upswing January 04, 2010 | Press Release
See all News
FDA Commissioner Dr. Margaret Hamburg headlines at the Burrill Annual Personalized Medicine Meeting
September 16, 2009New head of agency expected to provide perspective on regulatory policies and government initiatives.
SAN FRANCISCO - Newly confirmed FDA Commissioner Dr. Margaret Hamburg has vowed to enhance the FDA’s focus toward improving public health and at The Burrill Personalized Medicine Meeting, November 9-10 in San Francisco. Hamburg will provide attendees with the latest perspectives on regulatory policies and government initiatives that will help shape the adoption and impact of personalized medicine on healthcare.
SAN FRANCISCO - Newly confirmed FDA Commissioner Dr. Margaret Hamburg has vowed to enhance the FDA’s focus toward improving public health and at The Burrill Personalized Medicine Meeting, November 9-10 in San Francisco. Hamburg will provide attendees with the latest perspectives on regulatory policies and government initiatives that will help shape the adoption and impact of personalized medicine on healthcare.
Personalized medicine is the application of new methods of genetic analysis to diagnose, treat and manage disease – or predisposition of disease – on an individual basis. It has the power to transform healthcare within the foreseeable future, and is already having a disruptive impact on the U.S. healthcare system.
However, in order for personalized medicine to be fully adopted into clinical practice it will require changes in regulation, and legislative protections for privacy. Governments will need to play a bigger role in funding and coordinating research while also eliminating regulatory hurdles that currently hinder the creation and adoption of innovative products and medical treatments.
Dr. Hamburg will be speaking on the first day of the annual meeting now in its fifth year. Several sessions will focus on regulatory, reimbursement and government issues that could make or break the potential of personalized medicine.
Also on the first day Dr. George Poste, Chief Scientist, Complex Adaptive Systems Initiative at Arizona State University will present a second keynote entitled: “Health Technology Acceleration and Convergence,” where he will discuss the emergence of a new healthcare ecosystem based on increasingly comprehensive profiling of disease risk and health status.
“We are starting to see personalization of therapy become not just more widespread, but a best practice and a standard of care in certain disease areas. The pace of that trend will only increase as more and more targeted treatments reach the marketplace,” said G. Steven Burrill, CEO, Burrill & Company and organizer of the meeting.
The Burrill Personalized Medicine Meeting, will be held at the Mission Bay Conference Center at UCSF, 1675 Owens Street,San Francisco and feature detailed discussions on the whole spectrum of personalized medicine – from prediction to prevention – providing attendees with a detailed window into the personalized medicine world and the challenges and opportunities that this new paradigm presents.
Further details on the agenda may be obtained from: http://www.burrillandco.com/personalized_medicine_2009/
Contacts:
Events: Thea Johnson
Media: Peter Winter
Tel: 415-591-5474 Email: pwinter@b-c.com
###
Back to News list